Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agranulocytosis Therapy
Findings from Toho University advance knowledge in agranulocytosis therapy
June 26th, 2007
New investigation results, "The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease," are detailed in a study published in Endocrine Journal. According to a study from Tokyo, Japan, "The relation between the incidence of methimazole (methylmercaptoimidazole; MMI)-induced agranulocytosis and initial MMI dose was evaluated in a group of 514 patients with Graves' disease who were treated between 1995 and 2005. One hundred and forty-six (28.40%) patients had received an initial dose of 30 mg MMI and 277 (53.89%) patients had been treated with 15 mg MMI." "Nine patients (1.75%) developed...
Source: Drug Law Weekly (2007-06-26)
|
